Related Experiment Video
Updated: Jun 26, 2026

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine
Published on: February 9, 2016
A Questionnaire Survey on Long-Term Outcomes in Cats Breed-Screened for Feline Cardiomyopathy
Anna Follby1, Anna Pettersson2, Ingrid Ljungvall3
1AniCura Läckeby Djursjukhus, SE-395 98 Läckeby, Sweden.
Insights
Feline cardiomyopathy (FCM) significantly impacts cat health. Repeated screenings are vital, as cats diagnosed with FCM, even later in life, face a shorter lifespan and increased cardiac death risk.
Area of Science:
- Veterinary Cardiology
- Animal Health
- Genetics and Breeding
Background:
- Feline cardiomyopathy (FCM) is a primary cause of illness and death in cats.
- Breed screening for FCM (BS-FCM) aims to identify at-risk cats early.
- Long-term outcomes for cats undergoing FCM screening are not well-established.
Purpose of the Study:
- To investigate the long-term prognosis of cats screened for feline cardiomyopathy in Nordic countries.
- To evaluate the impact of FCM diagnosis timing on cardiac-related mortality and overall lifespan.
- To assess the necessity of repeated screening protocols for feline cardiomyopathy.
Main Methods:
- An explorative follow-up questionnaire study involving 1113 cats screened for FCM between 2004-2015.
- Analysis of medical records to identify cats diagnosed with FCM during or after the screening period.
- Comparison of survival times and causes of death between FCM-affected cats and those without FCM.
Main Results:
- 9.3% of screened cats developed FCM, with over half diagnosed during screening.
- Cats diagnosed with FCM, whether through screening or later reporting, had a higher risk of cardiac death.
- FCM-affected cats exhibited significantly shorter lifespans compared to unaffected cats.
Conclusions:
- A substantial percentage of cats develop FCM after initial screening, highlighting the need for repeated screenings.
- Early or later diagnosis of FCM is associated with reduced lifespan and increased cardiac mortality.
- Non-cardiac morbidities did not differ significantly across screening groups, suggesting FCM is the primary driver of mortality differences.
Abstract:
Feline cardiomyopathy (FCM) is an important contributor to feline morbidity and mortality. This explorative follow-up questionnaire study was aimed at investigating the long-term outcome in cats breed-screened for FCM (BS-FCM) in three Nordic countries. Records of cats with ≥1 BS-FCM between 2004−2015 were included. Of the 1113 included cats, 104/1113 (9.3%) had developed FCM at some time-point. Fifty-nine of the 104 (56.7%) FCM cats were diagnosed within the screening program (ScreenFCM), and 33/59 (55.9%) of these were diagnosed at the first BS-FCM. ScreenFCM cats or with an owner-reported FCM diagnosis at a later time-point had a higher risk of cardiac-related death compared to cats that never developed FCM. A shorter lifespan was found in ScreenFCM cats compared to those with normal screen results (p < 0.001). Times to all-cause mortality were shorter (p < 0.001) in cats that developed FCM at any time-point compared to those that did not. Non-cardiac morbidities were similar in all screen classification groups. The large proportion of cats that developed FCM at a later time-point underscores the need for repeated screenings later in life. Cats that developed FCM at any time-point had a shorter lifespan, with a similar proportion and in line with the nature of non-cardiac morbidities, compared to those without FCM.
Related Concept Videos
Longitudinal Research
Longitudinal Studies
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

